AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide TAIPEI, Oct. 5, 2026 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TPEx: 7754), a clinical-stage drug development company focused on
